Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(01): 48
DOI: 10.1055/s-0041-1733319
Letter to the Editor

COVID-19 Second Wave—The Tsunami and the Collapsing Indian Health Care Scene. Is Bevacizumab Strong Enough to Hold Fort

Sumant Gupta
1   Department of Medical Oncology, Sarvodaya Cancer Institute, Faridabad, Haryana, India
,
Neha Gupta
2   Department of Oncology, Sarvodaya Cancer Institute, Faridabad, Haryana, India
,
Faran Naim
2   Department of Oncology, Sarvodaya Cancer Institute, Faridabad, Haryana, India
,
Arvind Minz
3   Department of Internal Medicine, Sarvodaya Cancer Institute, Faridabad, Haryana, India
› Author Affiliations
› Further Information
   Permissions and Reprints
Zoom Image
Dr Sumant Gupta


Publication History

Article published online:
21 August 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Parikh P. COVID-19 Pandemic: Contrast Between SAARC Countries and Western World. 2020. Available at: https://www.m3india.in/contents/editor_pick/136721/covid-19-pandemic-contrast-between-saarc. Accessed on April 12, 2020
  • 2 Bhatraju PK, Ghassemieh BJ, Nichols M. et al. Covid-19 in critically ill patients in the Seattle region - case series. N Engl J Med 2020; 382 (21) 2012-2022
    CrossrefPubMedGoogle Scholar
  • 3 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10/223) 497-506
    CrossrefPubMedGoogle Scholar
  • 4 Jiaojiao Pang, Feng Xu. Efficacy and tolerability of bevacizumab in patients with severe Covid-19
  • 5 Islam MA, Mazumder MA, Akhter N. et al. Extraordinary survival benefits of severe and critical patients with COVID-19 by immune modulators: the outcome of a clinical trial in Bangladesh. Euroasian J Hepatogastroenterol 2020; 10 (02) 68-75
    PubMedGoogle Scholar